Recursive partitioning analysis of locoregional recurrence patterns following mastectomy: Implications for adjuvant irradiation

International Journal of Radiation Oncology Biology Physics

Volumn 50, Issue 2, 2001, Pages 397-403

  Katz, Angela ^a   Buchholz, Thomas A ^a   Thames, Howard ^a   Smith, Cynthia D ^a   McNeese, Marsha D ^a   Theriault, Richard ^a   Singletary, S Eva ^b   Strom, Eric A ^a  

^a Department of Radiation Oncology ^*  (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOTHERAPY; PATIENT MONITORING; RISKS; TUMORS;

ADJUVANT IRRADIATION; MASTECTOMY;

ONCOLOGY;

DOXORUBICIN; TAMOXIFEN;

ADULT; ARTICLE; BREAST CANCER; CANCER CENTER; CANCER RECURRENCE; CANCER STAGING; CHEMOTHERAPY; FEMALE; HISTOLOGY; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MASTECTOMY; PRIORITY JOURNAL; PROGNOSIS; RECURRENCE RISK; RISK FACTOR; STATISTICAL ANALYSIS; SURVIVAL TIME; TUMOR VOLUME;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; COHORT STUDIES; DOXORUBICIN; FEMALE; HUMANS; MASTECTOMY, MODIFIED RADICAL; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROGNOSIS; RADIOTHERAPY, ADJUVANT; SURVIVAL ANALYSIS;

EID: 0035370635     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0360-3016(01)01465-1     Document Type: Article

References (21)

1. Overgaard M., Hansen P.S., Overgaard J., et al. Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy. N Engl J Med. 337:1997;949-955.
2. Overgaard M., Hansen S., Rose P., et al. Randomized trial evaluating postoperative radiotherapy in high risk postmenopausal breast cancer patients given adjuvant tamoxifen Results from the DBCG 82c trial . Radiother Oncol. 48:1998;S78.
3. Ragaz J., Jackson S.M., Le N., et al. Adjuvant radiotherapy and chemotherapy in node-positive premenopausal women with breast cancer. N Engl J Med. 337:1997;956-962.
4. Recht A., Gray R., Davidson N.E., et al. Locoregional failure ten years after mastectomy and adjuvant chemotherapy with or without tamoxifen without irradiation Experience of the Eastern Cooperative Oncology Group . J Clin Oncol. 17:1999;1689-1700.
5. Fowble B., Gray R., Gilchrist K., et al. Identification of a subgroup of patients with breast cancer and histologically positive axillary nodes receiving adjuvant chemotherapy who may benefit from postoperative radiotherapy. J Clin Oncol. 6:1988;1107-1117.
6. Katz A., Strom E.A., Buchholz T.A., et al. Locoregional recurrence patterns following mastectomy and doxorubicin-based chemotherapy Implications for postoperative irradiation . J Clin Oncol. 18:2000;2817-2827.
7. Blumenschein G., Buzdar A.U., Hortobagyi G.N. FAC + BCG as adjuvant therapy in breast cancer An 8-year update . Rec Res Cancer Res. 96:1984;129-132.
8. Buzdar A., Blumenschein G.R., Smith T.L., et al. Adjuvant chemotherapy with fluorouracil, doxorubicin and cyclophosphamide with or without Bacillus Calmette-Guerin and with or without irradiation in operable breast cancer A prospective randomized trial . Cancer. 53:1984;384-389.
9. Buzdar A., Hortobagyi G.N., Marcus C.E., et al. Results of adjuvant chemotherapy trials in breast cancer at M. D. Anderson Hospital and Tumor Institute. NCI Monographs. 1:1986;81-85.
10. Buzdar A., Hortobagyi G.N., Smith T.L., et al. Adjuvant therapy of breast cancer with or without additional treatment with alternate drugs. Cancer. 62:1988;2098-2104.
11. Buzdar A., Kau S.W., Smith T.L. Ten-year results of FAC adjuvant chemotherapy trial in breast cancer. Am J Clin Oncol. 12:1989;123-128.
12. Buzdar A., Hortobagyi G.N., Kau S.W., et al. Adjuvant therapy with escalating doses of doxorubicin and cyclophosphamide with or without leukocyte alpha-interferon for stage II or III breast cancer. J Clin Oncol. 10:1992;1540-1546.
13. Theriault R., Buzdar A.U., Hortobagyi G.N., et al. Irradiation (XRT) following mastectomy in patients treated with FAC adjuvant therapy - MD Anderson Cancer Center experience. Proc Am Soc Clin Oncol. 10:1998;. (Abstr. 381).
14. Harris E., Albert A. Survivorship analysis for clinical studies. 1991;Dekker, New York.
15. Ciampi A., Change C.H., Hogg S., et al. Recursive partition A versatile method for exploratory data analysis . McNeil I., Umphrey G.J. Biostatistics. 1987;23-50 Reidel, New York.
16. Polychemotherapy for early breast cancer An overview of the randomized trials . Lancet. 352:1998;930-942.
17. Curran W.J., Scott C.B., Horton J., et al. Recursive partitioning analysis of prognostic factors in three Radiation Therapy Oncology Group malignant glioma trials [see comments]. J Natl Cancer Inst. 85:1993;704-710.
18. Scott C.B., Scarantino C., Urtasun R., et al. Validation and predictive power of Radiation Therapy Oncology Group (RTOG) recursive partitioning analysis classes for malignant glioma patients A report using RTOG 90-06 . Int J Radiat Oncol Biol Phys. 40:1998;51-55.
19. Komaki R., Scott C.B., Byhardt R., et al. Failure patterns by prognostic group determined by recursive partitioning analysis (RPA) of 1547 patients on four radiation therapy oncology group (RTOG) studies in inoperable nonsmall-cell lung cancer (NSCLC). Int J Radiat Oncol Biol Phys. 42:1998;263-267.
20. Zagars G.K., Pollack A., Smith L.G. Conventional external-beam radiation therapy alone or with androgen ablation for clinical stage III (T3, NX/N0, M0) adenocarcinoma of the prostate. Int J Radiat Oncol Biol Phys. 44:1999;809-819.
21. Iyer R.V., Hanlon A., Fowble B., et al. Accuracy of the extent of axillary nodal positivity related to primary tumor size, number of involved nodes, and number of nodes examined. Int J Radiat Oncol Biol Phys. 47:2000;1177-1183.